# ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma.

> **NCT07348107** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Daniel Breadner** · enrollment: 10 (estimated)

## Conditions studied

- Advanced Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** ATRA
- **DRUG:** Arsenic Trioxide (ATO)
- **DRUG:** Gemcitabine
- **DRUG:** Nab-paclitaxel
- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT07348107
- **Lead sponsor:** Daniel Breadner
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-15
- **Primary completion:** 2027-03
- **Final completion:** 2027-03
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-01-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07348107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07348107, "ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma.". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07348107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*